Jacobs Levy Equity Management
MRNA icon

Jacobs Levy Equity Management’s Moderna MRNA Stock Holding History

Jacobs Levy Equity Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-99,952
Closed -$5.08M – 1032
2026
Q1 		$5.08M Sell
99,952
-116,524
-54% -$5.44M 0.02% 414
2025
Q4 		$6.38M Sell
216,476
-1,233,455
-85% -$33.5M 0.02% 363
2025
Q3 		$37.5M Buy
1,449,931
+103,981
+8% +$2.9M 0.15% 140
2025
Q2 		$37.1M Buy
1,345,950
+347,447
+35% +$9.15M 0.15% 148
2025
Q1 		$28.3M Buy
+998,503
New +$35.4M 0.11% 186

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Jacobs Levy Equity Management's MRNA Position: Q2 2026 in Review

Jacobs Levy Equity Management sold out of Moderna (MRNA) in Q2 2026, closing a stake of 99,952 shares — an estimated $5.08M sold.

Jacobs Levy Equity Management first reported a position in MRNA in Q1 2025 and held it in 5 quarters. The position peaked at $37.5M in Q3 2025. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Jacobs Levy Equity Management reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 99,952 Moderna shares in Q2 2026, an estimated $5.08M.
  • Jacobs Levy Equity Management first reported a position in Moderna in Q1 2025 and held it in 5 quarters.
  • Jacobs Levy Equity Management's Moderna position peaked at $37.5M in Q3 2025.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.